Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Joint Venture, Subsidiary

Established: 1997-04-16

Employees: -

Market Cap: -

Website: http://www.cttq.com

Clinical Trials

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Phase 3

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Anlotinib hydrochloride capsule
Drug: Arotinib hydrochloride capsule placebo
Drug: Epirubicin

First Posted Date: 2021-11-16

Last Posted Date: 2022-02-18

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 256

Registration Number: NCT05121350

Locations: 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

Phase 2

Conditions: Endometrial Carcinoma

Interventions: Drug: TQB2858 injection
Drug: Anlotinib Hydrochloride capsules

First Posted Date: 2021-11-16

Last Posted Date: 2021-11-30

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 113

Registration Number: NCT05121363

Locations: 🇨🇳
Hunan Cancer Hospita, Changsha, Hunan, China
🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

Phase 1

Conditions: Advanced Malignant Tumors

Interventions: Drug: TQB3617

First Posted Date: 2021-11-08

Last Posted Date: 2022-02-14

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 38

Registration Number: NCT05110807

Locations: 🇨🇳
Sun Yat-sen University Cancer Cen, Guangzhou, Guangdong, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis

Phase 1

Not yet recruiting

Conditions: Type I Neurofibromatosis

Interventions: Drug: TQ-B3234 capsule

First Posted Date: 2021-11-04

Last Posted Date: 2021-11-04

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT05107037

Locations: 🇨🇳
Shanghai Ninth People's Hospital ，Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy

Phase 1

Conditions: Advanced Cervical Cancer

Interventions: Drug: TQB2858 injection

First Posted Date: 2021-10-06

Last Posted Date: 2021-12-13

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05068921

Locations: 🇨🇳
Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
🇨🇳
Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, China
🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

and more 12 locations

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Phase 2

Conditions: Unresectable Metastatic Colorectal Cancer

Interventions: Drug: AK105 injection
Drug: Anlotinib hydrochloride capsule
Drug: Bevacizumab
Drug: CapeOX

First Posted Date: 2021-10-05

Last Posted Date: 2021-10-20

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT05068206

Locations: 🇨🇳
Sun Yixian Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
The First Affiliated Hospital of Henan University of Scinece and Technology, Luoyang, Henan, China
🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China

and more 10 locations

A Clinical Trial of TQC3721 Suspension for Inhalation

Phase 1

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: TQC3721 suspension for inhalation
Drug: TQC3721 suspension placebo for inhalation

First Posted Date: 2021-09-21

Last Posted Date: 2021-10-25

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 114

Registration Number: NCT05051930

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors

Phase 1

Conditions: Solid Tumor

Interventions: Drug: TQB3811

First Posted Date: 2021-09-16

Last Posted Date: 2021-12-03

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT05046847

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Human Bioequivalence Test of Liraglutide Injection

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Liraglutide injection
Drug: Victoza

First Posted Date: 2021-08-31

Last Posted Date: 2021-08-31

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT05029076

Locations: 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China

A Clinical Study of TQB3824 in Subjects With Advanced Cancer

Phase 1

Recruiting

Conditions: Advanced Cancer

Interventions: Drug: TQB3824 tablets

First Posted Date: 2021-08-31

Last Posted Date: 2021-09-21

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 65

Registration Number: NCT05028218

Locations: 🇨🇳
Tianjin Medical University Cancer Institution & Hospital, Tianjin, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy